Palm-sized CRISPR sensing platform for on-site Mycoplasma pneumoniae detection

Area of Science:

• Molecular Biology
• Infectious Diseases
• Diagnostics

Background:

• Pneumonia is a leading cause of death in children under five.
• Mycoplasma pneumoniae causes frequent atypical pneumonia, raising global health concerns.
• Current diagnostic methods lack speed, affordability, and user-friendliness for widespread use.

Purpose of the Study:

• To develop a rapid, low-cost, and user-friendly CRISPR sensing platform for on-site Mycoplasma pneumoniae detection.
• To create a "sample in-result out" device for efficient M. pneumoniae diagnosis.
• To address the need for early detection of M. pneumoniae pneumonia, particularly in resource-limited settings.

Main Methods:

• Development of a CRISPR-based rapid assay device for field testing (CRAFT).
• Integration of sample processing, nucleic acid extraction, and CRISPR/Cas12a detection within a single device.
• Utilized recombinase polymerase amplification (RPA) and a magnetic bead valve for reagent isolation and mixing.

Main Results:

• CRAFT achieved sample processing and nucleic acid extraction in 5 minutes at room temperature.
• The limit of detection for M. pneumoniae was 100 copies/μL with no cross-reactivity with other pathogens.
• Clinical validation with 50 samples showed 100% consistency with quantitative PCR (qPCR) results.

Conclusions:

• CRAFT is a highly efficient and accurate platform for the rapid, on-site detection of Mycoplasma pneumoniae.
• The device demonstrates significant potential for point-of-care testing, especially in resource-limited environments.
• This innovation can improve early diagnosis and management of M. pneumoniae pneumonia in children.